COPPEBVCAD vs BEACOPP vs ABVD

This entry refers to a comparison of three multi-agent chemotherapy regimens used primarily in the treatment of hematologic malignancies such as Hodgkin lymphoma and certain aggressive lymphomas or leukemias. The regimens are: - **COPPEBVCAD**: No standard regimen by this exact name is recognized in major oncology references or guidelines. It appears to be either a typographical error or an uncommon/experimental combination not widely documented. - **BEACOPP**: A well-established combination chemotherapy regimen consisting of bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine, and prednisone. Used mainly for advanced-stage Hodgkin lymphoma. - **ABVD**: Another standard regimen for Hodgkin lymphoma composed of doxorubicin (Adriamycin), bleomycin, vinblastine, and dacarbazine. All these regimens act primarily as cytotoxic agents targeting rapidly dividing cancer cells through various mechanisms including DNA alkylation/crosslinking (cyclophosphamide, dacarbazine), inhibition of topoisomerase II (etoposide/doxorubicin), microtubule disruption (vincristine/vinblastine), free radical generation/DNA strand breaks (bleomycin/doxorubicin) and antimetabolite action.